Sodium-glucose cotransporter-2 (SGLT-2) inhibitors used to treat type 2 diabetes are associated with an 11% lower risk of autoimmune rheumatic diseases, such as rheumatoid arthritis and lupus, compared with another group of diabetes drugs called sulfonylureas, finds a study from South Korea published in The BMJ.
This article was originally published on MedicalXpress.com